StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report report published on Wednesday. The firm issued a sell rating on the stock.

Separately, Benchmark restated a hold rating on shares of VolitionRx in a report on Friday, August 16th.

VolitionRx Stock Performance

Shares of VNRX stock opened at $0.58 on Wednesday. The company has a market capitalization of $53.23 million, a price-to-earnings ratio of -1.26 and a beta of 1.12. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23. The company has a 50-day simple moving average of $0.65 and a two-hundred day simple moving average of $0.70.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.34 million. On average, sell-side analysts forecast that VolitionRx will post -0.31 EPS for the current fiscal year.

Insider Buying and Selling at VolitionRx

In other news, Director Guy Archibald Innes acquired 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was bought at an average price of $0.67 per share, with a total value of $100,500.00. Following the acquisition, the director now owns 406,683 shares in the company, valued at approximately $272,477.61. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 12.80% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.